The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Open accessAbstract
Although recurrent gene fusions involving erythroblastosis virus E26 transformation-specific (ETS) family transcription factors are common in prostate cancer, their products are considered 'undruggable' by conventional approaches. Recently, rare targetable gene fusions involving the anaplastic lymphoma receptor tyrosine kinase (ALK) gene, have been identified in 1–5% of lung cancers, suggesting that similar rare gene fusions may occur in other common epithelial cancers, including prostate cancer. Here we used paired-end transcriptome sequencing to screen ETS rearrangement–negative prostate cancers for targetable gene fusions and identified the SLC45A3-BRAF (solute carrier family 45, member 3–v-raf murine sarcoma viral oncogene homolog B1) and ESRP1-RAF1 (epithelial splicing regulatory protein-1–v-raf-1 murine leukemia viral oncogene homolog-1) gene fusions. Expression of SLC45A3-BRAF or ESRP1-RAF1 in prostate cells induced a neoplastic phenotype that was sensitive to RAF and mitogen-activated protein kinase kinase (MAP2K1) inhibitors. Screening a large cohort of patients, we found that, although rare, recurrent rearrangements in the RAF pathway tend to occur in advanced prostate cancers, gastric cancers and melanoma. Taken together, our results emphasize the key role of RAF family gene rearrangements in cancer, suggest that RAF and MEK inhibitors may be useful in a subset of gene fusion–harboring solid tumors and demonstrate that sequencing of tumor transcriptomes and genomes may lead to the identification of rare targetable fusions across cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Self-citationKleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Self-citationWilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Transcriptome sequencing to detect gene fusions in cancer
Maher, C. A., Kumar-Sinha, C., Cao, X., Kalyana-Sundaram, S., Han, B., Jing, X., Sam, L., Barrette, T., Palanisamy, N., & Chinnaiyan, A. M. (2009) · Nature · doi:10.1038/nature07638 · Cited by 900
Self-citation
Cited by
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
“RAF kinase fusions in 3% of mCPRC affected individuals would suggest the use of pan-RAF inhibitors or MEK inhibitors (Palanisamy et al., 2010).”
Self-citationThe Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citationRNA sequencing: advances, challenges and opportunities
Ozsolak, F., & Milos, P. M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2934 · Cited by 2,135
“This approach has led to important biological findings in oncolog”
BackgroundLessons from the Cancer Genome
Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,308
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,234
Self-citationAdvances in understanding cancer genomes through second-generation sequencing
Meyerson, M., Gabriel, S., & Getz, G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2841 · Cited by 1,116
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Integrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863
Self-citationTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Regulation of RAF protein kinases in ERK signalling
Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 702
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Wiesner, T., He, J., Yelensky, R., Esteve-Puig, R., Botton, T., Yeh, I., Lipson, D., Otto, G., Brennan, K., Murali, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4116 · Cited by 649
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Self-citationPersonalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Kalyana-Sundaram, S., Sam, L., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 628
Self-citationMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. A., Zhao, Y., Telenius, A., Neriah, S. B., et al. (2011) · Nature · doi:10.1038/nature09754 · Cited by 615
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Wu, Y.-M., Cieślik, M., Lonigro, R. J., Vats, P., Reimers, M. A., Cao, X., Ning, Y., Wang, L., Kunju, L. P., de Sarkar, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.034 · Cited by 598
Self-citationYao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.001 · Cited by 543
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, E. L., Durham, B. H., Haroche, J., Yao, Z., Ma, J., Parikh, S. A., Wang, Z., Choi, J., Kim, E., Cohen-Aubart, F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0913 · Cited by 535
Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma
Tan, P., & Yeoh, K.-G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.059 · Cited by 492
Self-citationTargeting Alterations in the RAF–MEK Pathway
Yaeger, R., & Corcoran, R. B. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1321 · Cited by 465
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Self-citationNew perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Raf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
Ren, S., Peng, Z., Mao, J.-H., Yu, Y., Yin, C., Gao, X., Cui, Z., Zhang, J., Yi, K., Xu, W., et al. (2012) · Cell Research · doi:10.1038/cr.2012.30 · Cited by 362
Bioprinting for cancer research
Knowlton, S., Onal, S., Yu, C. H., Zhao, J. J., & Tasoglu, S. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.06.007 · Cited by 361
Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.037 · Cited by 348
Next-generation sequencing in the clinic: Promises and challenges
Xuan, J., Yu, Y., Qing, T., Guo, L., & Shi, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.11.025 · Cited by 344
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 316
Common Gene Rearrangements in Prostate Cancer
Rubin, M. A., Maher, C. A., & Chinnaiyan, A. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.1916 · Cited by 307
Self-citationExpressed Pseudogenes in the Transcriptional Landscape of Human Cancers
Kalyana-Sundaram, S., Kumar-Sinha, C., Shankar, S., Robinson, D. R., Wu, Y.-M., Cao, X., Asangani, I. A., Kothari, V., Prensner, J. R., Lonigro, R. J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.041 · Cited by 301
Self-citationAn aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
Chen, M., Zhang, J., Sampieri, K., Clohessy, J. G., Mendez, L., Gonzalez-Billalabeitia, E., Liu, X.-S., Lee, Y.-R., Fung, J., Katon, J. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0027-2 · Cited by 293
Gerhauser, C., Favero, F., Risch, T., Simon, R., Feuerbach, L., Assenov, Y., Heckmann, D., Sidiropoulos, N., Waszak, S. M., Hübschmann, D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.016 · Cited by 293
ChimeraScan: a tool for identifying chimeric transcription in sequencing data
Iyer, M. K., Chinnaiyan, A. M., & Maher, C. A. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr467 · Cited by 276
Self-citationHovelson, D. H., McDaniel, A. S., Cani, A. K., Johnson, B., Rhodes, K., Williams, P. D., Bandla, S., Bien, G., Choppa, P., Hyland, F., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.03.004 · Cited by 224
Self-citationUncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo
Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.3 · Cited by 189
Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0896 · Cited by 171
Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
Wyatt, A. W., Mo, F., Wang, K., McConeghy, B., Brahmbhatt, S., Jong, L., Mitchell, D. M., Johnston, R. L., Haegert, A., Li, E., et al. (2014) · Genome Biology · doi:10.1186/s13059-014-0426-y · Cited by 82
Self-citationChapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64
Zheng, J., Zhao, S., Zhan, J., Zhuang, W., Chen, M., Jiang, W., Huang, Y., He, J., Hu, L., Pang, L., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1936 · Cited by 2
Metadata
- Authors
- Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., Kumar-Sinha, C., Dhanasekaran, S. M., Chen, Y.-B., Esgueva, R., Banerjee, S., LaFargue, C. J., Siddiqui, J., Demichelis, F., Moeller, P., Bismar, T. A., Kuefer, R., Fullen, D. R., Johnson, T. M., Greenson, J. K., Giordano, T. J., Tan, P., Tomlins, S. A., Varambally, S., Rubin, M. A., Maher, C. A., & Chinnaiyan, A. M.
- Venue
- Nature Medicine
- Published
- 2010-06-06
- Volume
- 16
- Issue
- 7
- Pages
- 793-798
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2029575024
- Cited by
- 464
- References
- 32
- FWCI
- 21.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.